Clinical Evidence Summary

EMTT: Why This Isn’t Just Another Electromagnetic Therapy

Reference: Hollander K et al. (2025), Journal of Back and Musculoskeletal Rehabilitation
Double-blind, placebo-controlled randomised controlled trial

She’d been through 12 weeks of physiotherapy for knee osteoarthritis: NSAIDs, activity modification, graded loading, all the right things, done well. And she was still in pain.

Sound familiar?

This is the patient sitting in front of most of us. The one who has done the work but still has not crossed the line. The chronic MSK patient who needs something more, but not surgery. That is exactly where Extracorporeal Magnetotransduction Therapy, or EMTT, is beginning to change the conversation, because the first robust RCT has now arrived.

Study Design
Double-blind, placebo-controlled RCT

Participants
126 chronic MSK patients

Protocol
8 weekly sessions, 20 minutes each

Key Takeaway
Significant pain and function gains

What is EMTT?

EMTT uses rapidly oscillating electromagnetic fields at high frequency, between 100 and 300 kHz, with high magnetic field strength of 80 mT to stimulate tissue at a cellular level. It is often mentioned alongside PEMF, but the two are fundamentally different.

PEMF operates at low frequencies below 100 Hz, weak field strengths under 8 mT, and typically requires daily use, sometimes for hours, over weeks to months. EMTT, by contrast, delivers more than 1,000 times the oscillation frequency, roughly 10 times the field strength, and a transduction power above 60 kT/s.

That transduction threshold matters because it is the level at which magnetically induced electrical impulses can trigger electroporation and piezoelectric effects in tissue. In practical terms, EMTT reaches deeper, works faster, and requires far fewer sessions than traditional electromagnetic therapies.

Feature PEMF EMTT
Frequency Below 100 Hz 100 to 300 kHz
Field Strength Under 8 mT 80 mT
Treatment Burden Daily use over weeks or months Short weekly sessions
Practical Implication Lower intensity, slower treatment course Deeper, faster, fewer sessions

The Study: Hollander et al. (2025)

This is the study many clinicians have been waiting for: a double-blind, placebo-controlled randomised trial of 126 patients across three of the most common degenerative MSK conditions seen in practice:

  • Knee osteoarthritis
  • Rotator cuff enthesopathy
  • Lumbar spondyloarthrosis

What makes this trial especially relevant is the patient population. Every participant had already failed at least six weeks of structured physiotherapy and pharmacological management before enrolment. These were not fresh referrals. These were the patients clinicians most often struggle with: the ones who have done everything right and are still stuck.

The methodology was strong. A custom-built sham device, developed with STORZ Medical, was visually and acoustically identical to the active unit but emitted no electromagnetic field. All prescription pain medication was washed out for a full week before treatment began, helping ensure the results reflected the independent effect of EMTT.

The Protocol

Sessions
8

Frequency
Once weekly

Session Length
20 minutes

Device
MAGNETOLITH

Settings: 80 mT magnetic field strength, 8 Hz impulse release frequency, 10,000 impulses per session

Application: Applicator placed directly on the skin over the target area

Practical advantage: No gels, no consumables, no patient downtime between sessions

The Results

Pain (VAS)

This is where the findings become especially compelling. At baseline, both groups were comparable, with VAS pain scores of 5.1 and 5.2 respectively. By six weeks post-treatment, the EMTT group had dropped to 2.8 compared with 4.3 in the placebo arm. By 12 weeks post-treatment, the gap widened further to 2.2 versus 4.2.

The effect sizes were large at both time points, and the continued improvement after treatment had finished suggests a sustained and progressive biological response rather than a short-term symptomatic effect.

Time Point EMTT Placebo p-value
Baseline 5.1 5.2 0.61 (ns)
6 weeks post-treatment 2.8 4.3 <0.0001
12 weeks post-treatment 2.2 4.2 <0.0001

Physical Function (SF-12 PCS)

Physical function followed the same trajectory. SF-12 Physical Component Summary scores improved to 42.9 versus 38.6 at six weeks, and to 45.5 versus 38.7 at 12 weeks, again with large effect sizes and high statistical significance.

Importantly, mental health composite scores did not differ between groups at any point. That suggests the benefit observed was genuinely physical rather than psychologically mediated or placebo-driven.

Time Point EMTT Placebo p-value
Baseline 34.4 35.3 0.09 (ns)
6 weeks post-treatment 42.9 38.6 <0.0001
12 weeks post-treatment 45.5 38.7 <0.0001

Consistency Across Conditions

The consistency across all three conditions was equally noteworthy. Whether the diagnosis was knee OA, rotator cuff enthesopathy, or lumbar spondyloarthrosis, the pattern held: statistically significant improvements in both pain and function at both six and 12 weeks. This was not a one-condition finding. It was a reproducible signal across different anatomical regions and different pathologies.

Is It Safe?

In short, yes. No serious adverse events were reported in any patient across either group.

Safety Finding EMTT Placebo Clinical Interpretation
Serious adverse events None None Strong safety signal
Localised skin redness Around 50% Around 10% Likely transient vasomotor response
Mild treatment discomfort 43% 18% Tolerable, no interrupted sessions

Beyond one day post-treatment, there was no significant difference in pain between the groups, suggesting EMTT does not provoke prolonged discomfort. In context, these effects appear milder than what many clinicians routinely see following manual therapy or injection-based interventions.

Why This Matters for MSK Therapists

Chronic MSK care is full of patients who have already done the right things yet remain symptomatic. EMTT does not replace good physiotherapy. It extends what clinicians can offer when the usual conservative pathway has reached its ceiling.

In this trial, patients had already completed physiotherapy and medication management and were still stuck. Eight 20-minute sessions later, they demonstrated clinically meaningful improvements in pain and function, and those gains continued to grow at 12 weeks.

For clinicians already using shockwave therapy, EMTT sits naturally alongside it as a complementary or standalone modality with a different mechanism but similarly practical delivery. For those not yet using it, this is the sort of evidence that changes the discussion: a double-blind, sham-controlled RCT with large effect sizes across three common conditions.

The Bigger Picture

The evidence journey is still early. More RCTs are needed, with larger samples, longer follow-up, and head-to-head comparisons with ESWT to clarify where EMTT fits within the treatment hierarchy.

Even so, the trajectory is already clear. EMTT appears safe, practical, and increasingly credible for chronic MSK patients who have run out of conservative options. The question is no longer whether the technology has potential. It is whether the profession is paying attention early enough.

Author

Benoy Mathew, MSc, MCSP
Advanced Practice Physio / MSK Sonographer
Head of MSK Education, Venn Healthcare

Twitter: @function2fitnes
Instagram: @function2fitness